Amr El-Karef

464 total citations
19 papers, 368 citations indexed

About

Amr El-Karef is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Amr El-Karef has authored 19 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 6 papers in Epidemiology and 5 papers in Oncology. Recurrent topics in Amr El-Karef's work include Liver physiology and pathology (5 papers), Liver Disease Diagnosis and Treatment (5 papers) and Liver Diseases and Immunity (4 papers). Amr El-Karef is often cited by papers focused on Liver physiology and pathology (5 papers), Liver Disease Diagnosis and Treatment (5 papers) and Liver Diseases and Immunity (4 papers). Amr El-Karef collaborates with scholars based in Egypt and Japan. Amr El-Karef's co-authors include Nashwa Abu‐Elsaad, Tarek M. Ibrahim, Esteban C. Gabazza, Tomohiro Nishioka, Teruyo Sakakura, Toshimichi Yoshida, Hiroyasu Inada, Kyoko Imanaka-Yoshida, Mamdouh M. El‐Shishtawy and Randa A. Zaghloul and has published in prestigious journals such as Life Sciences, European Journal of Pharmacology and The Journal of Pathology.

In The Last Decade

Amr El-Karef

19 papers receiving 367 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amr El-Karef Egypt 11 111 95 59 47 40 19 368
Hyemin Gu South Korea 15 164 1.5× 58 0.6× 31 0.5× 40 0.9× 16 0.4× 25 559
Ben Schroyen Belgium 7 144 1.3× 212 2.2× 98 1.7× 75 1.6× 8 0.2× 9 454
Kanda Kasetsinsombat Thailand 12 105 0.9× 46 0.5× 20 0.3× 57 1.2× 29 0.7× 19 545
Shuangsuo Dang China 12 136 1.2× 226 2.4× 180 3.1× 31 0.7× 10 0.3× 31 489
Lianyi Guo China 11 242 2.2× 60 0.6× 12 0.2× 73 1.6× 40 1.0× 30 531
Sapana Bansod India 11 103 0.9× 38 0.4× 23 0.4× 100 2.1× 13 0.3× 18 335
Clare A. Balendran Sweden 7 111 1.0× 157 1.7× 53 0.9× 69 1.5× 5 0.1× 11 394
Juliette Joubert‐Zakeyh France 12 148 1.3× 85 0.9× 60 1.0× 75 1.6× 4 0.1× 19 424
Yueqin Cai China 11 158 1.4× 55 0.6× 10 0.2× 37 0.8× 7 0.2× 24 394
Shuying Miao China 12 222 2.0× 68 0.7× 18 0.3× 35 0.7× 7 0.2× 22 526

Countries citing papers authored by Amr El-Karef

Since Specialization
Citations

This map shows the geographic impact of Amr El-Karef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amr El-Karef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amr El-Karef more than expected).

Fields of papers citing papers by Amr El-Karef

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amr El-Karef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amr El-Karef. The network helps show where Amr El-Karef may publish in the future.

Co-authorship network of co-authors of Amr El-Karef

This figure shows the co-authorship network connecting the top 25 collaborators of Amr El-Karef. A scholar is included among the top collaborators of Amr El-Karef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amr El-Karef. Amr El-Karef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
El-Karef, Amr, et al.. (2024). Empagliflozin protects the heart from atrial fibrillation in rats through inhibiting the NF-κB/HIF-1α regulatory axis and atrial remodeling. International Immunopharmacology. 143(Pt 2). 113403–113403. 2 indexed citations
2.
3.
Emile, Sameh Hany, et al.. (2024). Association between the expression of epithelial–mesenchymal transition (EMT)-related markers and oncologic outcomes of colorectal cancer. Updates in Surgery. 76(6). 2181–2191. 2 indexed citations
4.
El-Karef, Amr, et al.. (2023). Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. Environmental Toxicology and Pharmacology. 103. 104261–104261. 4 indexed citations
5.
6.
Abu‐Elsaad, Nashwa, et al.. (2021). Etanercept attenuates immune-mediated hepatitis induced by concanavalin A via differential regulation of the key effector cytokines of CD4+ T cells. Life Sciences. 277. 119618–119618. 10 indexed citations
7.
Abu‐Elsaad, Nashwa, et al.. (2019). Retinoic acid modulates IL-4, IL-10 and MCP-1 pathways in immune mediated hepatitis and interrupts CD4+ T cells infiltration. International Immunopharmacology. 75. 105808–105808. 17 indexed citations
8.
Abu‐Elsaad, Nashwa, et al.. (2019). Gum Acacia mitigates diclofenac nephrotoxicity by targeting monocyte chemoattractant protein-1, complement receptor-1 and pro-apoptotic pathways. Food and Chemical Toxicology. 129. 162–168. 15 indexed citations
9.
Abu‐Elsaad, Nashwa & Amr El-Karef. (2019). Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. Pharmacological Reports. 71(4). 688–694. 42 indexed citations
10.
Zaghloul, Randa A., Nehal M. Elsherbiny, Hany I. Kenawy, et al.. (2017). Hepatoprotective effect of hesperidin in hepatocellular carcinoma: Involvement of Wnt signaling pathways. Life Sciences. 185. 114–125. 45 indexed citations
11.
El-Karef, Amr, et al.. (2017). Insulin growth factor inhibitor as a potential new anti-schistosoma drug: An in vivo experimental study. Biomedicine & Pharmacotherapy. 95. 1346–1358. 6 indexed citations
12.
Abu‐Elsaad, Nashwa & Amr El-Karef. (2017). The Falconoid Luteolin Mitigates the Myocardial Inflammatory Response Induced by High-Carbohydrate/High-Fat Diet in Wistar Rats. Inflammation. 41(1). 221–231. 24 indexed citations
13.
Abu‐Elsaad, Nashwa, et al.. (2016). The vitamin D receptor agonist, calcipotriol, modulates fibrogenic pathways mitigating liver fibrosis in-vivo: An experimental study. European Journal of Pharmacology. 789. 362–369. 32 indexed citations
14.
Abu‐Elsaad, Nashwa, et al.. (2016). Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis. Canadian Journal of Physiology and Pharmacology. 94(7). 779–787. 21 indexed citations
15.
Abu‐Elsaad, Nashwa, et al.. (2015). Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats. Journal of Medicinal Food. 18(9). 950–959. 24 indexed citations
16.
El-Karef, Amr, et al.. (2015). Effect of Different Doses of Sitagliptin in Treatment of Experimentally Induced Colitis in Mice. British Journal of Pharmaceutical Research. 7(2). 140–151. 2 indexed citations
17.
Abu‐Elsaad, Nashwa, et al.. (2015). The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis. Naunyn-Schmiedeberg s Archives of Pharmacology. 388(12). 1293–1304. 13 indexed citations
18.
El-Karef, Amr, et al.. (2015). Comparative Study between Effect of Simvastatin (5 mg/Kg) and Simvastatin (50 mg/Kg) in an Early Treatment of Experimentally Induced Colitis in Mice. British Journal of Medicine and Medical Research. 8(11). 937–947. 3 indexed citations
19.
El-Karef, Amr, Toshimichi Yoshida, Esteban C. Gabazza, et al.. (2006). Deficiency of tenascin‐C attenuates liver fibrosis in immune‐mediated chronic hepatitis in mice. The Journal of Pathology. 211(1). 86–94. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyemin Gu Breakdown of academic impact, for papers by Ben Schroyen Breakdown of academic impact, for papers by Kanda Kasetsinsombat Breakdown of academic impact, for papers by Shuangsuo Dang Breakdown of academic impact, for papers by Lianyi Guo Breakdown of academic impact, for papers by Sapana Bansod Breakdown of academic impact, for papers by Clare A. Balendran Breakdown of academic impact, for papers by Juliette Joubert‐Zakeyh Breakdown of academic impact, for papers by Yueqin Cai Breakdown of academic impact, for papers by Shuying Miao
Rankless by CCL
2026